A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

LESSONS LEARNED: This study is a rare example of effective doses of both targeted agents being both administered and tolerated. This combination should not be used in melanoma. BACKGROUND. Sorafenib and bortezomib affect BCL family member expression. We previously demonstrated that bortezomib augmen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571786/
https://ncbi.nlm.nih.gov/pubmed/25986244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados